Flmodafinil: What It Is, What Is Known and What Is Not

Flmodafinil is the compound in this shop about which the least is known, and this page is written to say so plainly rather than to fill the gap with confident-sounding prose. It has no marketing authorisation anywhere in the European Union. No medicines regulator has assessed it. There is no approved patient information leaflet, no summary of product characteristics, no official list of side effects and no official contraindication list.

Contents

Everything below is either a printed particular of the product we sell, a matter of public record about the molecule and its patent history, or an honest statement that something is unknown. Where a fact does not exist, this page says so instead of borrowing one from a related substance.

An earlier version of this article was written the other way round. It carried a mechanism section, a pharmacokinetics section, a dosing section, a list of reported benefits and a head-to-head table scoring flmodafinil against modafinil. All of that has been removed on purpose, and the last section but one explains why.

What replaces it is longer, because the verifiable material — regulatory position, chemistry as composition, legal status by country, what a buyer can and cannot check, and what to do if something goes wrong — turns out to be more abundant than the pharmacology it replaces.

What flmodafinil is, and the names it goes by

Flmodafinil is a synthetic compound and a close structural relative of modafinil. It is not a brand name and it is not a medicine: it is a chemical identity, and the first useful thing to be able to do with it is recognise it under the several names it travels under, because a substance with five names is easy to buy twice by accident and easy to misread on a label.

The names in circulation for the same molecule are:

Where the compound came from, and who moved on from it

Its documented lineage runs through Lafon Laboratories in France, the company founded by the chemist Louis Lafon whose work produced modafinil in the first place. The fluorinated analogue was advanced more recently by NLS Pharmaceutics AG, a Swiss company, with the compound credited to the inventor Eric Konofal.

A United States patent application covering it was published in 2013 under the number US20130295196, and preclinical work is recorded from around December 2015. The company has since publicly reprioritised its development pipeline away from this compound. That is a corporate and regulatory history, and it is worth knowing precisely because it is the opposite of the “next-generation drug in development” framing the compound is usually sold with: the organisation that owned the programme moved on from it.

None of that history tells you anything about what the substance does in a person. A development code is an administrative label. A patent is a claim of novelty examined by a patent office, not a finding of efficacy or safety examined by a medicines authority — patent offices do not assess either, and a granted patent is not, and has never been, a health authorisation.

The chemistry, described as structure and nothing more

Flmodafinil is the bis(4-fluorophenyl) form of modafinil. In plain terms: modafinil’s structure carries two phenyl rings, and in flmodafinil each of those rings carries a fluorine atom at the para position. The molecular formula is C₁₅H₁₃F₂NO₂S and the molar mass is approximately 309.33 g/mol. The “fl” in the name refers to the fluorine; the rest of the name refers to the parent structure.

Two mirror-image forms, and which one is sold

Like modafinil, the molecule is chiral: it exists in two mirror-image forms, designated R and S, which contain the same atoms joined in the same order but are not superimposable, in the way that a left hand and a right hand are not. Material sold as flmodafinil is, unless a label says otherwise, the mixture of both forms rather than either one isolated. The separated single-enantiomer forms have been prepared in laboratories and given their own codes, but they are not what is sold.

Where descriptions of structure turn into claims

Fluorination is a routine tool in medicinal chemistry, and fluorine appears in a substantial share of modern pharmaceuticals. That is a fact about the discipline, not about this molecule. It is worth stating explicitly, because it is the point at which most writing about flmodafinil quietly changes register: a structural description of what was done to a molecule is turned, without any new evidence, into a claim about what the molecule now does in a body.

Those are different kinds of statement. Describing a structure — two fluorines, a defined formula, a defined mass, two enantiomeric forms — says precisely nothing about effect, duration, strength or safety in a person. It describes the thing; it does not describe what happens to the person who takes it. Any sentence that slides from one to the other without a human study in between is speculation dressed as chemistry, and this page does not make that move.

The regulatory position, stated without hedging

This is the section that matters most, and it is short because the facts are few and blunt.

Flmodafinil has no marketing authorisation anywhere in the European Union. It has not been authorised centrally by the European Medicines Agency, and it has not been authorised by any national medicines agency of any member state. It has no ATC classification.

It has not been approved by the United States Food and Drug Administration, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, or Australia’s Therapeutic Goods Administration, and it does not appear on the Australian Register of Therapeutic Goods. There is no jurisdiction known to us in which flmodafinil is an approved medicine for any purpose.

What is missing, item by item

“No marketing authorisation” sounds procedural. It is easier to see what it means by listing the specific documents that exist for an authorised medicine and do not exist for this one:

• No summary of product characteristics. For an authorised medicine, the SmPC is the reference document agreed with the regulator: composition, the authorised indication, contraindications, warnings, interactions, use in pregnancy and breastfeeding, and the full tabulated list of undesirable effects with their frequencies. For flmodafinil there is no such document, and nothing performs its function.
• No patient information leaflet. The leaflet in the box of an authorised medicine is a regulated document, written to an approved wording and updated when new safety information emerges. No flmodafinil product is supplied with one, because none exists to supply.
• No official side-effect list and no frequency data. Nobody has collected, assessed and published which effects occur and how often. Lists that circulate online are user reports or extrapolations from modafinil.
• No official contraindication list. No regulator has stated which conditions or co-medications make this compound inappropriate.
• No pharmacovigilance. There is no marketing authorisation holder obliged to collect suspected adverse reactions, no periodic safety update reporting, and no route by which a problem experienced by one person becomes information available to the next.
• No approved manufacturing dossier. No regulator has assessed a specification for the finished product, so there is no authorised standard against which a batch either passes or fails.

Which documents exist for what

Set against an authorised medicine in the EU, the same documents line up like this:

Why absence is a reason for caution, not a reassurance

The most common error made about unapproved compounds is to read a blank page as a clean one. It is not. A medicine with no listed side effects is not a medicine that has been shown to have none; it is a medicine nobody has been required to look at. A compound with no contraindications published is not a compound that is compatible with everything; it is a compound for which nobody has done the work of finding out what it is incompatible with.

An authorised medicine’s leaflet is long and often alarming precisely because somebody was obliged to compile it. The absence of that document does not remove the risks it would have described — it removes your ability to read about them in advance. That is the correct way to hold the flmodafinil situation in mind: the file is empty because it was never opened, and an empty file is a reason to take medical advice before use, not a reason to skip it.

The state of the evidence, and how to read it

There are no published controlled human trials of flmodafinil. There are no published human pharmacokinetic studies, no published efficacy trials and no published formal human safety data. This is not a matter of interpretation or of studies being small or conflicting; the studies do not exist.

What the published literature does contain

What does exist in the published literature is a small body of laboratory work — assays performed on isolated preparations rather than in people — and a small number of animal studies. Work of that kind is a normal and necessary early stage of research.

It is also, by design, incapable of answering the questions a person considering a purchase actually has, because it was never asked to. Laboratory and animal work speaks to whether a compound is worth studying further in humans. It does not establish what a human being should expect, and the history of pharmacology is substantially a history of compounds that looked promising at that stage and did not survive contact with a clinical trial.

What “research chemical” actually means

Flmodafinil is generally sold online under the label “research chemical“, frequently with the phrase “not for human consumption” printed alongside it. It is worth being exact about what that label is and is not.

It is not a category defined by any medicines regulator. It is not a quality grade, a purity standard or a certification. It is a commercial framing, and its function is jurisdictional: a product presented as a laboratory reagent rather than as something intended for people sits outside the medicines rules and outside most consumer-safety rules that would otherwise apply to it. That framing is doing legal work, not safety work.

Two consequences follow. First, the label tells you nothing about what is in the bottle — it is a statement about intended use, not about content.

Second, where a product is presented as not intended for human consumption, the protections a consumer would normally rely on may simply not be engaged. The phrase is best read as an indication of the regulatory space a product occupies, and never as a description of its quality or of anyone’s judgement about its safety.

Why forum reports are not evidence

The largest body of material about flmodafinil is user reports: forum threads, subreddit comments, video reviews, vendor testimonials. These are worth understanding on their own terms, because dismissing them as “just anecdotes” is glib, while treating them as data is worse.

The specific problems are structural rather than a matter of anyone lying:

• Nobody is blinded. Everyone writing a report knows what they took and knows what it is supposed to do. Expectation is not a minor contaminant of self-reported experience; in this domain it is one of the largest single influences on it, which is exactly why controlled trials go to the expense of concealing which participants received what.
• There is no control condition. A report describes a day. It cannot describe the same day without the substance, so it cannot separate the substance from sleep, caffeine, workload, stress, weather or the ordinary variation between one Tuesday and the next.
• Reporting is self-selected. People who noticed something write about it. People who noticed nothing mostly do not, and people who had a bad time often leave the community rather than post. What accumulates is therefore not a sample of experiences but a sample of the experiences that motivated somebody to type.
• The material is unattributable. Nobody knows what any given poster actually took: which supplier, which batch, which content, which contaminants. With an unapproved compound there is no batch-level accountability across the market, so two reports about “flmodafinil” may not be reports about the same material at all.
• Some of it is commercial. Vendor-adjacent posting is common in this category and is not always disclosed.

None of this makes user reports worthless as a description of what people believe they experienced. It makes them incapable of establishing that a substance does something, how often it does it, at what content, or at what risk. When a page cites “user reports” as the basis for a performance claim, it is citing the absence of evidence in a form designed to sound like its presence.

Legal status: not uniform, and subject to change

Because flmodafinil is not an authorised medicine anywhere in the EU, its legal treatment is not set by a single instrument, and there is no EU-wide answer to give. Several different bodies of law can touch it at once, and which of them applies depends on the country and sometimes on the circumstances of a particular consignment.

• Medicines law. A substance presented, marketed or supplied for an effect on the body can fall under national medicines legislation as an unlicensed medicinal product, regardless of what its label says about research use. Supplying an unlicensed medicinal product is restricted in every member state.
• Novel psychoactive substance frameworks. Several member states operate general laws covering psychoactive substances that are not individually scheduled. Germany’s Neue-psychoaktive-Stoffe-Gesetz is the most frequently cited example, and German import controls are applied more actively than in several neighbouring countries. A “research only” label does not reliably exempt a product from these frameworks.
• Analogue and structural-similarity provisions. Because modafinil is a prescription-only medicine across the EU and a controlled substance in a number of countries, a close structural relative marketed for an effect can attract scrutiny by analogy in several jurisdictions.
• Consumer and product-safety law. Products presented as not for human consumption may fall outside the protections a consumer would otherwise have, which is a legal fact with practical consequences if something goes wrong.

Outside the EU

Outside the EU the position is similarly unsettled:

Personal import and customs

Import is a separate question from possession, and the two are regularly confused. Whether a consignment may lawfully enter a country is decided by that country’s medicines and customs rules, not by the willingness of a shop to dispatch it. Customs authorities may inspect, detain, refuse entry to or destroy a consignment, and they may write to the addressee about it. A seller’s decision to ship to an address is a commercial decision. It is not a legal opinion about your situation, and nobody should read it as one.

NeuroPeak is a shop and not a legal adviser, and this page cannot tell you what applies where you live. What it can tell you is where to look: the national medicines agency of your country, its customs authority, and — if the position is not clear from those — a pharmacist or a legal source local to you. Do that before ordering rather than after, because the rules differ between neighbouring countries and are amended from time to time.

Competitive sport

Athletes subject to anti-doping rules should treat this compound as prohibited. The World Anti-Doping Agency’s Prohibited List names modafinil and armodafinil among stimulants, and its stimulant class is written to include other substances of similar chemical structure. A structural analogue of modafinil sits squarely inside that wording, and “it was not listed by name” has never been an accepted defence. Anyone competing under a code that adopts the WADA list should assume it is covered and check with their own anti-doping authority.

What a buyer can verify — and what cannot be verified

With an unapproved compound the honest question is not “is it good” but “what can actually be checked”. Some things can. Several important things cannot, and a shop that pretends otherwise is not being straight with you.

What is printed on the product

The flmodafinil we list is prepared and bottled under the NeuroPeak Labs name and supplied as a 30 mL dropper bottle. The label declares a concentration of 50 mg of flmodafinil per millilitre and a volume of 30 mL. The solution is carried in propylene glycol and PEG-400.

The bottle is sealed at filling and shipped sealed, with the batch number and the expiry date printed on the label, and the dropper supplied is the one the bottle was sealed with. Nothing is decanted, diluted, refilled or relabelled between the filling line and your address. Those are the particulars you can read for yourself and check against what arrives.

The format — a solution at a declared concentration per millilitre, supplied in a sealed 30 mL dropper bottle — is how the article is put up. That is a description of what you are buying, not an instruction from us about what to do with it. We give no administration instructions of any kind: no quantity, no schedule, no method. The product name the bottle is listed under in the catalogue is the supplier’s own, and nothing in it should be read as guidance from us either.

What the Certificate of Analysis does and does not say

Every batch is sampled on arrival at our EU warehouse and sent to an independent laboratory before it is listed for sale, and the Certificate of Analysis for that batch is available to download. The batch number on the bottle matches the certificate, so the analysis for the exact bottle in your hand can be requested and checked rather than taken on trust.

What the certificate establishes is identity and declared content: that the compound in the solution is the compound named, and that the concentration matches the figure on the label. That is genuinely worth having, and it is more than much of this market offers.

It is also the limit of what it establishes. A Certificate of Analysis is a document about the contents of a bottle. It is not evidence of an effect, it is not a safety assessment, it is not a substitute for a regulatory dossier, and it says nothing whatever about what the contents will do in any person. We do not present it as though it did, and you should be sceptical of any seller who does.

What cannot be verified

The list of things nobody can check for you is the more important half:

• Whether the compound is appropriate for you. No suitability criteria exist for an unassessed substance, so no shop can apply any. We apply none.
• What it does in a human being. There are no published human trials. No certificate, no laboratory report and no supplier can fill that gap.
• What quantity means what. There is no assessed content for this compound and therefore nothing for us or anyone else to state.
• How it interacts with your other medicines. Interaction studies have not been published. This cannot be ruled out, worked around or reassured away.
• What happens with continued use. There is no long-term human data of any kind.
• What other suppliers are selling. Purity, content and contamination vary across this market and self-declared purity figures such as “99%” are frequently just typed onto a label. A certificate applies to the batch it was issued for and to nothing else.

What we stock, who prepares it, and what it costs

One product, one presentation. Flmodafinil is listed under a single product name, as a 50 mg/mL solution in a 30 mL dropper bottle prepared and bottled under the NeuroPeak Labs name, stored sealed at our EU warehouse and dispatched sealed.

Pack options and price per bottle

The current pack options are:

Paying in Bitcoin takes 20% off the whole order automatically at checkout, with no coupon code to enter. Prices shown on the product page itself are read live from the catalogue, so where this article and the product page ever disagree, the product page is right.

Shipping, and what happens if it does not arrive

• Dispatch: orders leave our European distribution centre within 24 to 48 hours of payment confirmation.
• Tracked delivery: end to end, with the tracking number emailed on handover to the carrier, and typically 3 to 7 business days within the EU.
• Shipping cost: €4.95 to the Netherlands, €6.95 to Belgium and Germany and €9.95 to the rest of the EU and to the United Kingdom, Switzerland, Norway and Iceland, and free on orders over €150.
• Discreet packaging: the outer packaging is a plain, unmarked box with a neutral sender reference and nothing on it that indicates the contents.
• Delivery guarantee: if a tracked shipment does not arrive within the estimated window plus a five-business-day grace period, it is reshipped at no cost or refunded in full, at your choice, after the carrier record has been checked.

The current flmodafinil listing is on the product page, and the flmodafinil category shows whatever else is in stock.

Harm reduction where no official list exists

For an authorised medicine, this section would relay the leaflet. For flmodafinil there is no leaflet to relay, so what follows is the smaller set of things that can be said responsibly without one. It is deliberately not a translation of modafinil’s leaflet: whether the risks documented for modafinil apply to a structural analogue is unknown, and “unknown” cuts both ways — it is no basis for assuming they apply, and it is certainly no basis for assuming they do not.

Speak to a doctor or pharmacist first

Anyone considering this product should discuss it with a doctor or a pharmacist before use, and should mention every other medicine, every supplement and every health condition in that conversation. That advice is not a formality attached to the bottom of the page. It is the entire substitute for the assessment that a medicines regulator would otherwise have carried out, and it matters more here than it does for a product that arrives with a leaflet, not less.

Other medicines and conditions

Interactions with other medicines have not been studied and cannot be ruled out. Anyone taking any other medicine at all must take medical advice before use, and so must anyone in any of the following situations:

• a heart condition;
• high blood pressure;
• impaired liver or kidney function;
• a history of psychiatric illness;
• taking medicines for the heart or blood pressure;
• taking antidepressants or other medicines acting on the central nervous system;
• taking a monoamine oxidase inhibitor.

Hormonal contraception

It is documented that modafinil reduces the effectiveness of hormonal contraception, and that this covers every hormonal form:

• combined pills;
• progestogen-only pills;
• patches;
• implants;
• vaginal rings;
• hormonal intrauterine coils.

Whether the same applies to this analogue has not been established either way, and the absence of a study is not a finding of no interaction.

Anyone relying on hormonal contraception should therefore raise this specifically with a doctor or pharmacist before use and agree what additional or alternative contraception is appropriate, and should raise it again when stopping. This is the interaction most often left out of writing about this class of compound, and its consequences are the kind that do not reverse.

Pregnancy and breastfeeding

Do not use this product if you are pregnant, may become pregnant or are breastfeeding, without medical advice. There is no safety data in pregnancy for this compound, and the standard applied to an unassessed substance in pregnancy is caution rather than optimism.

Storage

Keep the bottle in its original packaging with the cap closed, at normal room temperature, dry and away from direct sunlight. Keep it out of the sight and reach of children — a dropper bottle of clear solution carries no tablet, no blister and no visual cue that it is anything other than an ordinary liquid, which makes secure storage more important here than for a boxed tablet, not less. Do not use the product after the expiry date printed on the label.

When to stop and seek urgent help

Stop and seek medical help immediately if any of the following occur:

• a skin rash, blistering, or ulceration of the mouth or eyes;
• swelling of the face or throat;
• difficulty breathing;
• fever;
• chest pain;
• an irregular heartbeat;
• hallucinations, agitation, confusion, depression or thoughts of self-harm.

A rash can be the first sign of a serious reaction and is a reason to stop and get medical attention rather than to wait and see. If any other reaction occurs, stop and take medical advice. Because no pharmacovigilance system covers this compound, there is nobody collecting these reports — your doctor is the only route by which what happens to you becomes information anyone acts on.

If something goes wrong, what to tell a clinician

A doctor treating a reaction can only work with what they are told, and with an unapproved compound there is no approved document on file to fill the gaps. Take the bottle with you, or photograph the label before you go. What matters to whoever is treating you is:

• the substance name and the other names it travels under;
• the declared concentration and volume printed on the label;
• the batch number;
• the supplier;
• when it was taken and how much;
• every other medicine, supplement and substance involved.

Say plainly that the compound holds no marketing authorisation and that no approved product information exists for it: that tells a clinician immediately that there is no monograph to look up and that they are treating what is in front of them. Keep the Certificate of Analysis for the batch to hand as well if you can. It says nothing about what the contents do in a person, but it does establish what was in the bottle, which is more than is usually available in this situation.

Two further points that belong with that

Nobody collects these reports centrally — there is no marketing authorisation holder and no pharmacovigilance obligation attached to this compound — so telling your own doctor, and where your country operates one, the national reporting scheme for suspected adverse reactions, is the only route by which what happened to you becomes information anyone else can act on.

And treat the ordinary precaution that a leaflet would set out as applying here in the absence of one: do not drive or operate machinery while assessing an unfamiliar substance whose effects nobody has characterised in a controlled human study, and do not combine it with alcohol or with other substances without medical advice.

Why this page publishes no comparison of effect

An earlier version of this article contained a table comparing flmodafinil with modafinil row by row: relative potency per milligram, onset, duration, how long the effect was said to last, and a summary of which was described as cleaner. It also contained a ranking of flmodafinil against armodafinil and adrafinil. Those tables have been deleted, and they will not be coming back.

Why the comparisons were not true in the sense a reader would take them

The reason is not squeamishness. Two products containing the same substance at the same declared strength are not two different things: one does not begin sooner, run longer or land harder than the other.

Where the substances differ, the honest position is that establishing a difference in effect requires human trials that, for flmodafinil, do not exist — so a table putting flmodafinil in a column next to modafinil and awarding it a multiplier is not reporting a comparison, it is manufacturing one. The numbers in such tables come from patent language, laboratory assays, animal work and forum posts, and the arrow points the same way every time: towards the product with the higher margin.

What this site compares instead

So this site publishes no comparison of effect between brands, between presentations or between substances, and no ranking by onset, strength or smoothness, for any product in the catalogue. We do compare two things, because they are real and printed: who makes a product, and what it costs per unit.

Everything else that gets tabulated in this market is marketing wearing the clothes of pharmacology. Saying so costs us a section that used to convert well, and it is still the right call — a reader who has been told plainly which claims a shop cannot back is in a better position than one who has been handed a table.

Frequently asked questions

Is flmodafinil an approved medicine anywhere in the EU?

No. It has no marketing authorisation from the European Medicines Agency or from any national medicines agency in any member state, and no ATC classification. It is also unapproved in the United States, the United Kingdom and Australia. There is no jurisdiction known to us in which it is an approved medicine for any purpose.

Are there human clinical trials of flmodafinil?

No published controlled human trials exist. There are no published human pharmacokinetic studies and no published human safety data. The published literature consists of laboratory assays and a small number of animal studies, which is the stage of research that decides whether a compound is worth testing in people — not a stage that tells you anything about the result.

What does “no leaflet” actually mean for me?

It means there is no regulator-approved document listing this compound’s side effects, their frequencies, its contraindications, its interactions or its use in pregnancy, because no regulator has assessed it and no marketing authorisation obliges anyone to compile one. It also means there is no pharmacovigilance system collecting reports of problems. Read the blank page as an absence of scrutiny rather than an absence of risk.

Why is it sold labelled “research chemical”?

Because it has no medical approval anywhere, sellers present it as a laboratory reagent rather than as something intended for people, which places it outside medicines regulation and outside most consumer-safety rules. The label is a regulatory framing, not a quality grade, not a purity standard and not anyone’s safety endorsement. It also tells you nothing about what is in the bottle.

Is it legal where I live?

We cannot answer that, and no shop can. There is no EU-wide rule: medicines law, novel psychoactive substance frameworks and analogue provisions apply differently in different member states, and Germany in particular applies import controls more actively than several of its neighbours. Check with your national medicines agency and customs authority before ordering, and ask a pharmacist or a local legal source if the position is not clear.

What can I actually check about the bottle I receive?

The supplier name, the declared concentration of 50 mg per millilitre, the 30 mL volume, the carrier solution of propylene glycol and PEG-400, the batch number, the expiry date and the intact seal. The batch number matches the Certificate of Analysis, which confirms the identity of the compound and its declared concentration. What you cannot check — from any document — is what the contents will do in a person.

Does the Certificate of Analysis mean the product has been approved?

No, and the two should never be confused. A Certificate of Analysis is an independent laboratory’s statement about what is in a specific batch. Approval is a medicines authority’s assessment of quality, safety and efficacy for a defined use. This compound has the first and has never had the second, anywhere.

Why does the article not tell me how much to take?

Because no assessed quantity exists for this compound, so there is nothing for anyone to state. We are a shop, not a pharmacy: we hold nobody’s medical history, we assess nobody and we issue no prescriptions, which leaves us with no basis whatever for saying what quantity suits any individual. That conversation belongs with a doctor or pharmacist.

Where has the comparison table gone?

It was removed on purpose. It ranked flmodafinil against modafinil on potency, onset and duration using figures drawn from patent claims, laboratory assays and forum posts rather than from human studies. This site now publishes no comparison of effect between products or substances at all — only the manufacturer and the price per unit, which are the two things printed on a label.

Is it prohibited in competitive sport?

Treat it as prohibited. The WADA Prohibited List names modafinil and armodafinil among stimulants and the class is drafted to cover substances of similar chemical structure. Anyone competing under a code that adopts that list should check with their own anti-doping authority rather than relying on the compound not being named.

How is it shipped, and what if it does not arrive?

Orders leave our EU warehouse within 24 to 48 hours, travel tracked end to end and typically take 3 to 7 business days within the EU, in plain unmarked outer packaging with a neutral sender reference. Shipping is free over €150. If a tracked shipment has not arrived within the estimated window plus a five-business-day grace period, we reship it at no cost or refund it in full, at your choice, after checking the carrier record.

The bottom line

Flmodafinil is a structurally interesting molecule with a documented patent history, a handful of laboratory and animal studies behind it, a company that has moved on from developing it, and no authorisation, no leaflet, no assessed side-effect list and no human trials anywhere in the world. That is the whole of what is known, and the honest version of this page is shorter on claims than the version it replaces because most of what used to be here was not knowledge.

What we can offer is a product whose particulars are printed and checkable, a batch analysis you can match to the bottle in your hand, a clear account of the legal position and where to verify it for your own country, and a refusal to pretend that any of that adds up to an assessment nobody has made.

If you want the parts of this category that do come with a regulator’s file behind them, modafinil and armodafinil are authorised as substances in EU member states, unlike flmodafinil, and the product information agreed for the authorised medicines — a summary of product characteristics and a patient leaflet — is published in the national medicines registers for anyone to read.

The tablets in our modafinil and armodafinil categories are not those authorised medicines: they are Indian-Pharmacopoeia generics holding no EU marketing authorisation of their own, and what is supplied in the carton is the manufacturer’s leaflet rather than a regulator-approved one. Whatever you decide, decide it with a doctor or pharmacist who knows your history, and check the law where you live before you order.

Questions this page has not answered are covered on our FAQ page, or you can contact us directly. The questions we cannot answer are what quantity to take, when to take it and whether it suits you — not because we are being coy, but because nobody has established the answers and we will not invent them.

NeuroPeak is a shop, not a pharmacy, and this article is not medical advice. Flmodafinil is not an authorised medicine in the European Union or elsewhere: no regulator has assessed it, there is no approved patient information leaflet and there are no published human clinical trials. Nothing here is intended to diagnose, treat, cure or prevent any condition. Consult a qualified healthcare professional before use, and confirm the legal position in your own country before ordering.